Blood pressure drug joins fight against tough head & neck cancers
NCT ID NCT06211335
Summary
This early-stage study is testing the safety of a three-part treatment for head and neck cancer that has come back, spread a little, or hasn't responded to other treatments. It combines a common blood pressure medicine (losartan) with an immunotherapy drug (pembrolizumab) and very precise, high-dose radiation (SBRT). The goal is to see if this combination is safe and can help control the cancer better than current options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California Davis Comprehensive Cancer Center
RECRUITINGSacramento, California, 95817, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Colorado Denver | Anschutz Medical Campus
RECRUITINGAurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.